MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.23.00720

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.

Vergote Ignace, Van Nieuwenhuysen Els, O'Cearbhaill Roisin E, Westermann Anneke, Lorusso Domenica, Ghamande Sharad, Collins Dearbhaile C, Banerjee Susana, Mathews Cara A, Gennigens Christine, Cibula David, Tewari Krishnansu S, Madsen Kristine, Köse Fatih, Jackson Amanda L, Boere Ingrid A, Scambia Giovanni, Randall Leslie M, Sadozye Azmat, Baurain Jean-François, Gort Eelke, Zikán Michal, Denys Hannelore G, Ottevanger Nelleke, Forget Frédéric, Mondrup Andreassen Camilla, Eaton Lamar, Chisamore Michael J, Viana Nicacio Leonardo, Soumaoro Ibrahima, Monk Bradley J

Многоцентровое исследованиеКлиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).

METHODS

This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR).

RESULTS

A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).

CONCLUSION

TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.

Для цитирования: Vergote Ignace, Van Nieuwenhuysen Els, O'Cearbhaill Roisin E, Westermann Anneke, Lorusso Domenica, Ghamande Sharad, Collins Dearbhaile C, Banerjee Susana, Mathews Cara A, Gennigens Christine, Cibula David, Tewari Krishnansu S, Madsen Kristine, Köse Fatih, Jackson Amanda L, Boere Ingrid A, Scambia Giovanni, Randall Leslie M, Sadozye Azmat, Baurain Jean-François, Gort Eelke, Zikán Michal, Denys Hannelore G, Ottevanger Nelleke, Forget Frédéric, Mondrup Andreassen Camilla, Eaton Lamar, Chisamore Michael J, Viana Nicacio Leonardo, Soumaoro Ibrahima, Monk Bradley J. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. DOI: 10.1200/jco.23.00720.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.